Congenital factor XIII deficiency

Congenital factor XIII deficiency (also known as congenital FXIII deficiency or Laki-Lorand factor deficiency) is a rare inherited bleeding disorder caused by a deficiency or dysfunction of coagulation factor XIII, the last enzyme in the coagulation cascade. Factor XIII is responsible for cross-linking fibrin to stabilize blood clots, and its deficiency leads to the formation of fragile clots that break down prematurely. The condition primarily affects the hematologic system but can have serious consequences across multiple organ systems due to uncontrolled bleeding. The hallmark clinical features include umbilical cord stump bleeding in neonates (occurring in up to 80% of affected individuals), a highly characteristic early sign that often leads to diagnosis. Other key symptoms include delayed soft tissue bleeding after trauma or surgery, recurrent subcutaneous hematomas, muscle hemorrhages, hemarthrosis (joint bleeding), prolonged wound healing, and a significant risk of life-threatening intracranial hemorrhage, which is the leading cause of death in untreated patients. Women with severe deficiency frequently experience recurrent miscarriages due to defective placental implantation, as well as menorrhagia. Congenital FXIII deficiency is classified into two subtypes: type A (more common, approximately 95% of cases), caused by mutations in the F13A1 gene encoding the catalytic A subunit, and type B (rare, approximately 5%), caused by mutations in the F13B gene encoding the carrier B subunit. Standard coagulation screening tests such as PT and aPTT are typically normal, making diagnosis challenging; specific FXIII activity assays and clot solubility tests are required. Treatment consists of regular prophylactic replacement therapy with plasma-derived FXIII concentrate (such as Corifact/Fibrogammin) or recombinant FXIII-A2 (Tretten/NovoThirteen), which has dramatically improved outcomes. Due to the long half-life of factor XIII (approximately 9-12 days), prophylactic infusions are typically needed only once monthly, making management relatively convenient compared to other severe bleeding disorders.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Congenital factor XIII deficiency